Plus Therapeutics (Plus Therapeutics) EBIT per Share : $-3.10 (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics EBIT per Share?

Plus Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.75. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.10.

During the past 3 years, the average EBIT per Share Growth Rate was 49.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 57.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 64.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Plus Therapeutics's EBIT per Share or its related term are showing as below:

PSTV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -37.3 Med: 29.2 Max: 84.1
Current: 49.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Plus Therapeutics was 84.10% per year. The lowest was -37.30% per year. And the median was 29.20% per year.

PSTV's 3-Year EBIT Growth Rate is ranked better than
93.33% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs PSTV: 49.30

Plus Therapeutics's EBIT for the three months ended in Mar. 2024 was $-3.23 Mil.

Plus Therapeutics EBIT per Share Historical Data

The historical data trend for Plus Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics EBIT per Share Chart

Plus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-15.52

-24.18

-15.47

-11.18

-4.11

Plus Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-2.01	-0.55	-0.97	-0.83	-0.75

Plus Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Plus Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-12.921	/	3.141
=	-4.11

Plus Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.227	/	4.322
=	-0.75

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10

Plus Therapeutics (NAS:PSTV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Plus Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics (Plus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.

Executives

Marc H Hedrick	officer: President	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk	director	LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes	director	217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen	director	3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre	officer: Chief Financial Officer	4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance	officer: CHIEF MEDICAL OFFICER	MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance	10 percent owner	MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote	10 percent owner	CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell	director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino	officer: Chief Medical Officer	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris	officer: VP and GM of Cell Therapy	3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey	director